Literature DB >> 6467684

The failure of ascorbic acid therapy to alter the induction or remission of murine amyloidosis.

M L Baltz, D Caspi, B E Glatthaar, U Moser, M B Pepys.   

Abstract

It has been claimed that ascorbic acid enhances the in vitro degradation of AA amyloid fibrils. This raises the possibility that ascorbic acid may be of benefit in systemic AA amyloidosis, a condition with serious morbidity and mortality for which there is as yet no specific treatment. The effect was therefore tested of oral or injected supplements of ascorbic acid on the induction of AA amyloidosis in mice. Amyloid was induced either by repeated injections of casein or by injection of 'amyloid enhancing factor' and silver nitrate. Mice with established amyloidosis were also treated with additional ascorbic acid. Despite the fact that plasma ascorbic acid levels were significantly higher in orally supplemented mice than in controls there was no demonstrable effect on the induction, the extent and distribution or the progression of amyloidosis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6467684      PMCID: PMC1536279     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  Experimental Amyloidosis in the Guinea Pig.

Authors:  C L Pirani; C G Bly; K Sutherland; F Chereso
Journal:  Science       Date:  1949-08-05       Impact factor: 47.728

2.  Amyloid-related serum component (SAA)--studies in acute infections, medullary thyroid carcinoma, and postsurgery.

Authors:  P D Gorevic; C J Rosenthal; E C Franklin
Journal:  Clin Immunol Immunopathol       Date:  1976-07

Review 3.  Amyloid deposits and amyloidosis: the beta-fibrilloses (second of two parts).

Authors:  G G Glenner
Journal:  N Engl J Med       Date:  1980-06-12       Impact factor: 91.245

4.  The role of inflammatory cells in the pathogenesis of amyloidosis.

Authors:  R Kisilevsky; M Axelrad; W Corbett; S Brunet; F Scott
Journal:  Lab Invest       Date:  1977-12       Impact factor: 5.662

5.  Cortisone-ascorbic acid interaction and the pathogenesis of amyloidosis; mechanism of action of cortisone on mesenchymal tissue.

Authors:  G TEILUM
Journal:  Ann Rheum Dis       Date:  1952-06       Impact factor: 19.103

6.  Changes in human serum amyloid A and C-reactive protein after etiocholanolone-induced inflammation.

Authors:  K P McAdam; R J Elin; J D Sipe; S M Wolff
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

7.  Amyloid P-component in mice injected with casein: identification in amyloid deposits and in the cytoplasm of hepatocytes.

Authors:  M L Baltz; R F Dyck; M B Pepys
Journal:  Immunology       Date:  1980-09       Impact factor: 7.397

8.  Variation with age and disease of an amyloid A protein-related serum component.

Authors:  C J Rosenthal; E C Franklin
Journal:  J Clin Invest       Date:  1975-04       Impact factor: 14.808

9.  Characteristics of the amyloid A fibril-degrading activity of human serum.

Authors:  A M Teppo; C P Maury; O Wegelius
Journal:  Scand J Immunol       Date:  1982-10       Impact factor: 3.487

10.  Reduced amyloid-A-degrading activity in serum in amyloidosis associated with rheumatoid arthritis.

Authors:  O Wegelius; A M Teppo; C P Maury
Journal:  Br Med J (Clin Res Ed)       Date:  1982-02-27
View more
  1 in total

1.  'Amyloid degrading activity' of human serum, an in vitro clearing effect which does not involve degradation of amyloid fibrils.

Authors:  D Caspi; M L Baltz; A Feinstein; E A Munn; M B Pepys
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.